Terms: = Ovarian cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K
1411 results:
1. Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.
Liang H; Geng S; Wang Y; Fang Q; Xin Y; Li Y
J Cell Mol Med; 2024 May; 28(9):e18315. PubMed ID: 38680032
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
3. Endometriosis-Associated ovarian cancer: From Molecular Pathologies to Clinical Relevance.
Steinbuch SC; Lüß AM; Eltrop S; Götte M; Kiesel L
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673891
[TBL] [Abstract] [Full Text] [Related]
4. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
5. MATN2 overexpression suppresses tumor growth in ovarian cancer via PTEN/pi3k/AKT pathway.
Liu J; Zhang J; Zhang Y; Yang B; Liu H; Chen Y
Funct Integr Genomics; 2024 Apr; 24(2):71. PubMed ID: 38568332
[TBL] [Abstract] [Full Text] [Related]
6. Diosgenin inhibits proliferation and migration of ovarian cancer cells and induce apoptosis via upregulation of PTEN.
Fang F; Zhang X; Fang Y
Chem Biol Drug Des; 2024 Mar; 103(3):e14459. PubMed ID: 38538058
[TBL] [Abstract] [Full Text] [Related]
7. The roles of autophagy, ferroptosis and pyroptosis in the anti-ovarian cancer mechanism of harmine and their crosstalk.
Zhu J; Zhu H; Zhu Q; Xu SL; Xiao L; Zhang MY; Gao J
Sci Rep; 2024 Mar; 14(1):6504. PubMed ID: 38499622
[TBL] [Abstract] [Full Text] [Related]
8. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
[TBL] [Abstract] [Full Text] [Related]
9. AKTing on R Loops Makes for an ATRactive Target in ovarian cancer Therapy.
Ramanarayanan V; Oberdoerffer P
Cancer Res; 2024 Mar; 84(6):793-795. PubMed ID: 38486481
[TBL] [Abstract] [Full Text] [Related]
10. Clonal origin and genomic diversity in Lynch syndrome-associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of MLH1 p.L582H.
Takahashi K; Yachida N; Tamura R; Adachi S; Kondo S; Abé T; Umezu H; Nyuzuki H; Okuda S; Nakaoka H; Yoshihara K
Genes Chromosomes Cancer; 2024 Mar; 63(3):e23231. PubMed ID: 38459936
[TBL] [Abstract] [Full Text] [Related]
11. Periostin's role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma.
Kiesler ZG; Hunter MI; Balboula AZ; Patterson AL
Arch Gynecol Obstet; 2024 May; 309(5):1825-1831. PubMed ID: 38441600
[TBL] [Abstract] [Full Text] [Related]
12. TMED3 stabilizes SMAD2 by counteracting NEDD4-mediated ubiquitination to promote ovarian cancer.
Chen X; Zhang W; Han X; Li X; Xia L; Wu Y; Zhou Y
Mol Carcinog; 2024 May; 63(5):803-816. PubMed ID: 38411267
[TBL] [Abstract] [Full Text] [Related]
13. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via pi3k-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
14. Novel prognostic marker TGFBI affects the migration and invasion function of ovarian cancer cells and activates the integrin αvβ3-pi3k-Akt signaling pathway.
Wang H; Xu YH; Guo Y
J Ovarian Res; 2024 Feb; 17(1):50. PubMed ID: 38395907
[TBL] [Abstract] [Full Text] [Related]
15. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
16. VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.
Wang Q; Tang Y; Dai A; Li T; Pei Y; Zhang Z; Hu X; Chen T; Chen Q
Appl Microbiol Biotechnol; 2024 Feb; 108(1):218. PubMed ID: 38372808
[TBL] [Abstract] [Full Text] [Related]
17. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating pi3k/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract] [Full Text] [Related]
18. β-Sitosterol targets ASS1 for Nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN/pi3k/AKT signaling pathway in ovarian cancer.
Wang H; Liu J; Zhang Z; Peng J; Wang Z; Yang L; Wang X; Hu S; Hong L
Free Radic Biol Med; 2024 Mar; 214():137-157. PubMed ID: 38364944
[TBL] [Abstract] [Full Text] [Related]
19. ITGB2 fosters the cancerous characteristics of ovarian cancer cells through its role in mitochondrial glycolysis transformation.
Li GW; Jin YP; Qiu JP; Lu XF
Aging (Albany NY); 2024 Feb; 16(3):3007-3020. PubMed ID: 38345576
[TBL] [Abstract] [Full Text] [Related]
20. Differential expression of follicular fluid exosomal microRNA in women with diminished ovarian reserve.
Xie Y; Chen J; Liu K; Huang J; Zeng Y; Gao M; Qian Y; Liu L; Tan Y; Nie X
J Assist Reprod Genet; 2024 Apr; 41(4):1087-1096. PubMed ID: 38321265
[TBL] [Abstract] [Full Text] [Related]
[Next]